{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122766","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.865390+00:00","generated_at":"2026-05-30T03:47:31.124997+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Monte Rosa reports Q3 net loss $23.9M; announces Novartis deal for VAV1 degraders with $150M upfront","bullets":["Net loss of $23.9M for Q3 2024; collaboration revenue of $9.2M from Roche.","Global license with Novartis for VAV1 MGDs: $150M upfront, up to $2.1B milestones, U.S. P&L share.","MRT-6160 Phase 1 SAD/MAD ongoing; initial safety and PD data expected by Q1 2025.","MRT-2359 Phase 1/2 in MYC-driven tumors; updated results and Phase 2 guidance by year-end 2024.","Cash $247.1M at Sept 30; plus $150M Novartis upfront extends runway into 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122766","json":"https://secwatch.observer/filing/0000950170-24-122766.json","markdown":"https://secwatch.observer/filing/0000950170-24-122766.md","text":"https://secwatch.observer/filing/0000950170-24-122766.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000095017024122766/0000950170-24-122766-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000095017024122766/glue-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:47:31.124997+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}